SRP230618 Track Settings
 
Differential DNA methylation profiles of HS ILAE type 1 in human temporal lobe epilepsy [Brain; Hippocampus]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD       HMR      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
experiment
SRX7182824 
SRX7182825 
SRX7182826 
SRX7182827 
SRX7182828 
SRX7182829 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX7182824  HMR  Brain; Hippocampus / SRX7182824 (HMR)   schema 
hide
 SRX7182824  CpG reads  Brain; Hippocampus / SRX7182824 (CpG reads)   schema 
hide
 SRX7182824  CpG methylation  Brain; Hippocampus / SRX7182824 (CpG methylation)   schema 
hide
 SRX7182824  AMR  Brain; Hippocampus / SRX7182824 (AMR)   schema 
hide
 SRX7182824  PMD  Brain; Hippocampus / SRX7182824 (PMD)   schema 
hide
 SRX7182825  CpG reads  Brain; Hippocampus / SRX7182825 (CpG reads)   schema 
hide
 SRX7182825  CpG methylation  Brain; Hippocampus / SRX7182825 (CpG methylation)   schema 
hide
 SRX7182825  AMR  Brain; Hippocampus / SRX7182825 (AMR)   schema 
hide
 SRX7182825  PMD  Brain; Hippocampus / SRX7182825 (PMD)   schema 
hide
 SRX7182825  HMR  Brain; Hippocampus / SRX7182825 (HMR)   schema 
hide
 SRX7182826  CpG reads  Brain; Hippocampus / SRX7182826 (CpG reads)   schema 
hide
 SRX7182826  CpG methylation  Brain; Hippocampus / SRX7182826 (CpG methylation)   schema 
hide
 SRX7182826  AMR  Brain; Hippocampus / SRX7182826 (AMR)   schema 
hide
 SRX7182826  PMD  Brain; Hippocampus / SRX7182826 (PMD)   schema 
hide
 SRX7182826  HMR  Brain; Hippocampus / SRX7182826 (HMR)   schema 
hide
 SRX7182827  CpG reads  Brain; Hippocampus / SRX7182827 (CpG reads)   schema 
hide
 SRX7182827  CpG methylation  Brain; Hippocampus / SRX7182827 (CpG methylation)   schema 
hide
 SRX7182827  AMR  Brain; Hippocampus / SRX7182827 (AMR)   schema 
hide
 SRX7182827  PMD  Brain; Hippocampus / SRX7182827 (PMD)   schema 
hide
 SRX7182827  HMR  Brain; Hippocampus / SRX7182827 (HMR)   schema 
hide
 SRX7182828  CpG reads  Brain; Hippocampus / SRX7182828 (CpG reads)   schema 
hide
 SRX7182828  CpG methylation  Brain; Hippocampus / SRX7182828 (CpG methylation)   schema 
hide
 SRX7182828  AMR  Brain; Hippocampus / SRX7182828 (AMR)   schema 
hide
 SRX7182828  PMD  Brain; Hippocampus / SRX7182828 (PMD)   schema 
hide
 SRX7182828  HMR  Brain; Hippocampus / SRX7182828 (HMR)   schema 
hide
 SRX7182829  CpG reads  Brain; Hippocampus / SRX7182829 (CpG reads)   schema 
hide
 SRX7182829  CpG methylation  Brain; Hippocampus / SRX7182829 (CpG methylation)   schema 
hide
 SRX7182829  AMR  Brain; Hippocampus / SRX7182829 (AMR)   schema 
hide
 SRX7182829  PMD  Brain; Hippocampus / SRX7182829 (PMD)   schema 
hide
 SRX7182829  HMR  Brain; Hippocampus / SRX7182829 (HMR)   schema 
    

Study title: Differential DNA methylation profiles of HS ILAE type 1 in human temporal lobe epilepsy
SRA: SRP230618
GEO: GSE140658
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX7182824 Brain; Hippocampus 0.795 17.5 57006 1268.1 625 824.3 3225 23789.2 0.992 GSM4176376: C1; Homo sapiens; Bisulfite-Seq
SRX7182825 Brain; Hippocampus 0.794 16.6 52206 1226.4 726 849.8 3030 25017.8 0.991 GSM4176377: C2; Homo sapiens; Bisulfite-Seq
SRX7182826 Brain; Hippocampus 0.805 17.0 52665 1171.3 662 841.8 3436 19607.5 0.992 GSM4176378: C3; Homo sapiens; Bisulfite-Seq
SRX7182827 Brain; Hippocampus 0.800 16.7 55204 1256.0 497 811.5 3360 22947.6 0.992 GSM4176379: I1-1; Homo sapiens; Bisulfite-Seq
SRX7182828 Brain; Hippocampus 0.788 20.7 58859 1152.1 1366 897.9 2939 24415.9 0.989 GSM4176380: I1-2; Homo sapiens; Bisulfite-Seq
SRX7182829 Brain; Hippocampus 0.780 19.2 58555 1177.9 1006 903.0 3145 24622.3 0.989 GSM4176381: I1-3; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.